Giuseppe Gargiulo
Overview
Explore the profile of Giuseppe Gargiulo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
183
Citations
2452
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Acute Heart Failure and Non-Ischemic Cardiomyopathies: A Comprehensive Review and Critical Appraisal
Manzi L, Buongiorno F, Narciso V, Florimonte D, Forzano I, Castiello D, et al.
Diagnostics (Basel)
. 2025 Mar;
15(5).
PMID: 40075788
Acute heart failure (AHF) is a complex clinical syndrome characterized by the rapid or gradual onset of symptoms and/or signs of heart failure (HF), leading to an unplanned hospital admission...
2.
Kang J, Gargiulo G
Eur Heart J Cardiovasc Pharmacother
. 2024 Nov;
11(1):45-47.
PMID: 39558848
No abstract available.
3.
Fiorillo G, Ghazihosseini S, Agizza S, Lanza F, Piccirillo S, Gargiulo G, et al.
J Med Case Rep
. 2024 Nov;
18(1):524.
PMID: 39506764
Background: The complications associated with cardiac device implants ranges between 5.3% and 14.3%. Cardiac perforation due to "leads" represent a very rare complication of cardiac device implantation, ranging between 0.3%...
4.
Galli M, Gragnano F, Berteotti M, Marcucci R, Gargiulo G, Calabro P, et al.
JACC Cardiovasc Interv
. 2024 Oct;
17(20):2325-2336.
PMID: 39477636
Over the past decades, there have been great advancements in the antithrombotic management of patients undergoing percutaneous interventions, but most of the available evidence derives from studies conducted in the...
5.
Galli M, Gragnano F, Berteotti M, Marcucci R, Gargiulo G, Calabro P, et al.
JACC Cardiovasc Interv
. 2024 Oct;
17(19):2197-2215.
PMID: 39415380
Antithrombotic therapy after cardiac percutaneous interventions is key for the prevention of thrombotic events but is inevitably associated with increased bleeding, proportional to the number, duration, and potency of the...
6.
Manzi L, Florimonte D, Forzano I, Buongiorno F, Sperandeo L, Castiello D, et al.
Interv Cardiol Clin
. 2024 Sep;
13(4):527-541.
PMID: 39245552
Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is fundamental in all patients undergoing percutaneous coronary intervention (PCI) to prevent coronary thrombosis. In patients with atrial fibrillation (AF), an...
7.
Nardi E, Santoro C, Prastaro M, Canonico M, Paolillo S, Gargiulo G, et al.
Cardiooncology
. 2024 Aug;
10(1):48.
PMID: 39113118
Atrial fibrillation (AF) is more common in patients with malignancies than in general population. The pathophysiological processes include the pro-inflammatory condition and the exaggerated inflammatory reaction to chemotherapy, radiotherapy, and...
8.
Sciahbasi A, De Rosa S, Gargiulo G, Giacoppo D, Calabro P, Talarico G, et al.
J Cardiovasc Pharmacol
. 2024 Jul;
84(4):457-467.
PMID: 39028879
In patients on oral anticoagulant (OAC) therapy undergoing percutaneous coronary intervention (PCI) with stent, international guidelines endorse the use of direct oral anticoagulants (DOAC) rather than vitamin K antagonists (VKA)...
9.
Piccolo R, Simonetti F, Avvedimento M, Cutillo M, Canonico M, Conti V, et al.
Eur Heart J Cardiovasc Pharmacother
. 2024 Jul;
10(7):578-587.
PMID: 39025785
Aims: Although dual antiplatelet therapy with aspirin and a potent P2Y12 receptor inhibitor is currently recommended in patients with acute coronary syndrome (ACS), its use in elderly patients remains challenging....
10.
Landi A, Gargiulo G, Esposito G, Campo G, Biscaglia S, Heg D, et al.
Thromb Res
. 2024 Mar;
237:31-33.
PMID: 38547691
No abstract available.